GSK-LSD1 Dihydrochloride is primarily used in research settings to study the role of LSD1 (lysine-specific demethylase 1) in various biological processes. It serves as a potent and selective inhibitor of LSD1, which is an enzyme involved in the demethylation of histone proteins. By inhibiting LSD1, this compound helps researchers explore its impact on gene expression, particularly in the context of cancer and other diseases where epigenetic regulation is critical. It is also utilized in the development of potential therapeutic strategies targeting epigenetic modifications, especially in oncology, to understand how LSD1 inhibition can affect tumor growth and progression. Additionally, it aids in investigating the broader implications of epigenetic modulation in cellular differentiation and development.